Scientists developed curcumin nanoparticles and evaluated their cytotoxicity in docetaxel (DTX)-resistant castration-resistant prostate cancer (CRPC) cells for the treatment of DTX-resistant CRPC.
1254621 N8EW4QIJ items 1 apa default asc 1
Researchers integrated a computational proteochemometric systems network pharmacology platform, DrugGenEx‐Net, with primary, continuous cultures of conditionally reprogrammed normal and prostate cancer (PCa) cells derived from treatment‐naive patients with primary PCa.
1254621 28RGHG5A items 1 apa default asc 1
Naeem, A., Dakshanamurthy, S., Walthieu, H., Parasido, E., Avantaggiati, M., Tricoli, L., Kumar, D., Lee, R. J., Feldman, A., Noon, M. S., Byers, S., Rodriguez, O., & Albanese, C. (n.d.). Predicting new drug indications for prostate cancer: The integration of an in silico proteochemometric network pharmacology platform with patient-derived primary prostate cells. The Prostate, n/a(n/a). https://doi.org/10.1002/pros.24050 Cite
Researchers review the current status of immunotherapy, including new discoveries and precision approaches to prostate cancer, and discuss future directions in the continuously evolving landscape of immunotherapy.
[International Journal of Molecular Sciences]
The addition of chelerythrine significantly inhibited the proliferation of androgen-independent prostate cancer DU145 and PC-3 cells at the concentration of 5 and 10 μM, but not on androgen-dependent prostate cancer LNCaP cells as well as normal prostate epithelial cell line PrEC cells.
[Molecular and Cellular Biochemistry]
1254621 4TPRTHZM items 1 apa default asc 1
ORIC Pharmaceuticals, Inc. announced it has entered into an exclusive worldwide license agreement with Mirati Therapeutics, Inc. ORIC will have exclusive worldwide rights for the development activities and commercialization of a small molecule allosteric inhibitor program directed towards the polycomb repressive complex 2, a validated oncogenic target across several cancers with promising therapeutic potential in prostate cancer, among other indications.
[ORIC Pharmaceuticals, Inc.]
Scientists determined the effects of grape antioxidants quercetin and/or resveratrol against prostate cancer in the transgenic adenocarcinoma of mouse prostate (TRAMP)-model in prevention and intervention settings.
1254621 XTSV5X7K items 1 apa default asc 1
Scientists hypothesized that designed peptides with a wide spectrum of selective antimicrobial activity will also have anticancer activity, and tested this hypothesis with newly designed peptides.
1254621 8I2RKNLQ items 1 apa default asc 1
Juretić, D., Golemac, A., Strand, D. E., Chung, K., Ilić, N., Goić-Barišić, I., & Pellay, F.-X. (2020). The Spectrum of Design Solutions for Improving the Activity-Selectivity Product of Peptide Antibiotics against Multidrug-Resistant Bacteria and Prostate Cancer PC-3 Cells. Molecules, 25(15), 3526. https://doi.org/10.3390/molecules25153526 Cite
The authors investigated whether δ-tocotrienol (δ-TT) might exert its activity by impairing mitochondrial functions. They demonstrated that, in PC3 and DU145 cells, δ-TT impairs mitochondrial respiration and structural dynamics.
[Free Radical Biology and Medicine]
1254621 EPC4SE5M items 1 apa default asc 1
Fontana, F., Raimondi, M., Marzagalli, M., Audano, M., Beretta, G., Procacci, P., Sartori, P., Mitro, N., & Limonta, P. (2020). Mitochondrial functional and structural impairment is involved in the antitumor activity of δ-tocotrienol in prostate cancer cells. Free Radical Biology and Medicine. https://doi.org/10.1016/j.freeradbiomed.2020.07.009 Cite
Scientists evaluated the antitumor effect of a next‐generation analog of ralaniten as a monotherapy or in combination with enzalutamide in prostate cancer cells that express AR‐V7 that were resistant to enzalutamide.
1254621 IEV78KG5 items 1 apa default asc 1
Hirayama, Y., Tam, T., Jian, K., Andersen, R. J., & Sadar, M. D. (n.d.). Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. Molecular Oncology, n/a(n/a). https://doi.org/10.1002/1878-0261.12770 Cite
Researchers confirmed autophagy induction by withaferin A (WA) treatment by transmission electron microscopy using three prostate cancer cell lines. Fourteen common genes altered by 8‐ and 16‐hour exposure to WA were identified from human autophagy PCR array and these results were consistent with the RNA‐seq data.
Immunogenic cell death was determined by assessing the release of damage-associated molecular patterns in the prostate cancer-derived cell lines LNCaP, 22RV1 and PC-3.
1254621 4XP9LYBB items 1 apa default asc 1
The authors examined the potential of natural AKR1C3 inhibitors in various prostate cancer cell lines and a three-dimensional co-culture spheroid model consisting of cancer cells and cancer-associated fibroblasts mimicking enzalutamide resistant prostate cancer.
1254621 NA2BLJMC items 1 apa default asc 1
Kafka, M., Mayr, F., Temml, V., Möller, G., Adamski, J., Höfer, J., Schwaiger, S., Heidegger, I., Matuszczak, B., Schuster, D., Klocker, H., Bektic, J., Stuppner, H., & Eder, I. E. (2020). Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer. Cancers, 12(8), 2092. https://doi.org/10.3390/cancers12082092 Cite